ACOG endorses HPV self‑collection as a routine option for average‑risk cervical screening
- The American College of Obstetricians and Gynecologists updated its cervical cancer screening guidance to add self-collected human papillomavirus testing as a routine option for average-risk patients ages 30 to 65. - The revised guidance keeps the same age bands but now lists three choices for ages 30 to 65: primary HPV testing every five years, co-testing every five years, or cytology alone every three years. - The change aligns ACOG with the Women’s Preventive Services Initiative after the Food and Drug Administration cleared home-collection HPV testing this week. (womenspreventivehealth.org) (fda.gov)
Human papillomavirus, or HPV, is the virus that causes nearly all cervical cancers, and screening looks for warning signs before cancer develops. The American College of Obstetricians and Gynecologists now says some patients can collect the HPV sample themselves as a routine option. (acog.org) ACOG’s updated guidance applies to average-risk people ages 30 to 65. In that group, screening options now include primary HPV testing every five years with either a clinician-collected or self-collected sample, co-testing every five years, or cytology alone every three years. (acog.org) (womenspreventivehealth.org) For ages 21 to 29, the guidance still recommends cervical cytology alone every three years. Screening before age 21 is still not recommended for average-risk patients. (acog.org) (womenspreventivehealth.org) Self-collection means the patient uses a swab to collect a vaginal sample for HPV testing instead of having a clinician collect a cervical sample during a pelvic exam. The policy change is limited to average-risk screening, not people with higher-risk histories who may need different follow-up. (womenspreventivehealth.org) (acog.org) The timing matters because the Food and Drug Administration said on April 24, 2026, that it approved the first home-collection HPV test. That decision opened a path for patients to collect samples outside a clinic setting. (fda.gov) The Women’s Preventive Services Initiative had already updated its recommendation to include self-collected HPV testing for average-risk patients ages 30 to 65. ACOG said its guidance is consistent with that recommendation. (womenspreventivehealth.org) (acog.org) Cervical cancer screening has been moving away from relying only on the Pap test because HPV testing can identify the virus that drives most cases before abnormal cells appear. The updated menu keeps Pap-based options in place while adding another way to do HPV-based screening. (acog.org) (womenspreventivehealth.org) The practical question now is how clinicians and laboratories handle sample collection, processing, and follow-up when a self-collected HPV test is positive. ACOG’s update gives that workflow a place inside routine screening rather than treating it as an exception. (acog.org) (fda.gov) For patients who have delayed screening because of pelvic exams, the new option changes the front end of the test, not the goal. The aim is still the same: find HPV or abnormal cells early enough to prevent cervical cancer. (acog.org) (womenspreventivehealth.org)
